[1]张耀,郑莎,周吉军,等.拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2008,30(09):848-850.
 ZHANG Yao,ZHENG Sha,ZHOU Ji-jun,et al.Efficacy of lamivudine in treatment on HBV-related liver failure:Meta analysis study[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(09):848-850.
点击复制

拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
30卷
期数:
2008年第09期
页码:
848-850
栏目:
论著
出版日期:
2008-05-15

文章信息/Info

Title:
Efficacy of lamivudine in treatment on HBV-related liver failure:Meta analysis study
作者:
张耀郑莎周吉军王宇明
第三军医大学西南医院:全军感染病研究所,全军眼科中心
Author(s):
ZHANG Yao ZHENG Sha ZHOU Ji-jun WANG Yu-ming
Institute of Infectious Diseases, Department of Ophthalmology; Southwest Hospital, Third Military Medical University
关键词:
拉米夫定 肝衰竭 预后 Meta分析
Keywords:
lamivudine liver failure prognosis Meta analysis
分类号:
R195.4; R575.305; R978.7
文献标志码:
A
摘要:
目的  系统评价拉米夫定治疗乙型肝炎病毒(HBV)相关性肝衰竭的疗效。  方法  检索1989年1月至2007年7月有关在常规内科治疗的基础上加用拉米夫定后对患者病死率、总胆红素(TBIL)及凝血酶原活动度(PTA)影响的文献,应用Meta分析的方法以比值比(OR)或加权平均数(WMD)为效应量进行合并分析。  结果  上述研究指标纳入研究文献分别为13、10篇和10篇,合并效应量及95%可信限(95% CI)分别为0.29(95%CI:0.21,0.40)、-0.88(95%CI:-1.27,-0.48)和0.60(95%CI:0.42,0.78)。  结论  与常规内科治疗组比较,加用拉米夫定可以显著降低肝衰竭患者的病死率,改善患者的TBIL和PTA水平。
Abstract:
Objective  To evaluate the therapeutic effect of lamivudine in the treatment of HBV-related liver failure.   Methods  We collected the literature on lamivudine used to treat liver failure in randomized control trail or clinical control trial studies from January 1989 to July 2007. All these clinical trials were carried out by comparing lamivudine treatment with routine medical treatment for liver failure. The literature must concern about mortality, total bilirubin (TBIL) or prothrombin activity (PTA). Odds ratio (OR) was applied to evaluate the effect of glucocorticoid to improve case fatality. Weighted mean differences (WMD) was applied to evaluate the effect of  lamivudine to improve TBIL and PTA.   Results  There were only 13 literatures obtained, among them all about mortality, and 10 about TBIL and PTA. Effective index was 0.29 (95%CI: 0.21, 0.40), -0.88 (95%CI: -1.27, -0.48) and 0.60 (95%CI: 0.42, 0.78) respectively for the 3 indexes.   Conclusion  Combination with lamivudine is more effective in treatment liver failure than only routine medical treatment.

相似文献/References:

[1]张南,夏杰,邓国宏,等.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):75.
 ZHANG Nan,XIA Jie,DENG Guo-hong,et al.Effect of lamivudine on survival rate of patients with chronic severe hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(09):75.
[2]肖吉,陈文,刘玉元,等.拉米夫定治疗HBeAg阴性慢性乙型肝炎疗效相关因素分析[J].陆军军医大学学报(原第三军医大学学报),2011,33(08):835.
 Xiao Ji,Chen Wen,Liu Yuyuan,et al.Analysis of factors related to lamivudine efficacy in treating HBeAg-negative chronic hepatitis B[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(09):835.
[3]李玲,毛青,黄燕萍,等.慢性乙型肝炎患者HBV DNA YMDD变异的检测及意义[J].陆军军医大学学报(原第三军医大学学报),2005,27(02):167.
[4]何登明,毛青,王宇明,等.拉米夫定疗程中慢性乙型肝炎患者血清IL-12水平和Th平衡变化及其意义[J].陆军军医大学学报(原第三军医大学学报),2004,26(19):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
 HE Deng-ming,MAO Qing,WANG Yu-ming,et al.[J].J Amry Med Univ (J Third Mil Med Univ),2004,26(09):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
[5]黄燕萍,王宇明.拉米夫定治疗50例慢性乙型肝炎患者自身前后对照试验[J].陆军军医大学学报(原第三军医大学学报),2002,24(11):0.[doi:10.16016/j.1000-5404.2002.11.055 ]
 HUANG Yan ping,WANG Yu ming.[J].J Amry Med Univ (J Third Mil Med Univ),2002,24(09):0.[doi:10.16016/j.1000-5404.2002.11.055 ]

更新日期/Last Update: 2008-05-08